Effects of O-methylated (−)-epigallocatechin gallate (EGCG) on LPS-induced osteoclastogenesis, bone resorption, and alveolar bone loss in mice

Tsukasa Tominari1, Ryota Ichimaru1, Shosei Yoshinouchi1, Chiho Matsumoto1, Kenta Watanabe2, Michiko Hirata1, Florian M.W. Grundler3, Masaki Inada1,2 and Chisato Miyaura1,2

1 Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Koganei, Japan
2 Institute of Global Innovation Research, Tokyo University of Agriculture and Technology, Koganei, Japan
3 Institute of Crop Science and Resource Conservation, University of Bonn, Germany

Keywords
bone resorption; lipopolysaccharide; O-methylated EGCG; periodontitis

Correspondence
C. Miyaura, Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Nakacho, Koganei, Tokyo 184-8588, Japan
Tel: +81 42 388 7390
E-mail: miyaura@cc.tuat.ac.jp
(Received 28 July 2017, revised 30 September 2017, accepted 19 October 2017)

doi:10.1002/2211-5463.12340

(−)-Epigallocatechin-3-O-gallate (EGCG), present in green tea, exhibits antioxidant and antiallergy effects. EGCG3″Me, a 3-O-methylated derivative of EGCG, has been reported to show similar biological functions; the inhibitory activity of EGCG3″Me in a mouse allergy model was more potent than that of EGCG, probably due to the efficiency of absorption from the intestine. However, the functional potency of these EGCGs is controversial in each disease model. We previously observed that EGCG suppressed inflammatory bone resorption and prevented alveolar bone loss in a mouse model of periodontosis. In this study, we examined the role of EGCG3″Me in bone resorption using a mouse model of periodontitis. Lipopolysaccharide (LPS)-induced osteoclast formation was suppressed by adding EGCG3″Me to cocultures of osteoblasts and bone marrow cells, and LPS-induced bone resorption was also inhibited by EGCG3″Me in calvarial organ cultures. EGCG3″Me acted on osteoblasts and suppressed prostaglandin E (PGE) production, which is critical for inflammatory bone resorption, by inhibiting the expression of COX-2 and mPGES-1, key enzymes for PGE synthesis. In osteoclast precursor macrophages, EGCG3″Me suppressed RANKL-dependent differentiation into mature osteoclasts. In a mouse model of periodontitis, LPS-induced bone resorption was suppressed by EGCG3″Me in organ culture of mouse alveolar bone, and the alveolar bone loss was further attenuated by the treatment of EGCG3″Me in the lower gingiva in vivo. EGCG3″Me may be a potential natural compound for the protection of inflammatory bone loss in periodontitis.

Bone remodeling is precisely regulated by a balance of osteoclastic bone resorption and osteoblastic bone formation. Receptor activator of NF-κB ligand (RANKL) is expressed on the cell surface of osteoblasts in response to bone-resorbing factors, such as lipopolysaccharide (LPS), interleukin (IL)-1, and tumor necrosis factor (TNF)-α [1–3]. RANK is expressed on osteoclast precursor cells, and osteoblast-

Abbreviations
BMMs, bone marrow macrophages; COX-2, cyclooxygenase-2; EGCG, (−)-epigallocatechin-3-O-gallate; EGCG3″Me, O-methylated (−)-epigallocatechin gallate; IL-1, interleukin-1; LPS, lipopolysaccharide; mPGES-1, membrane-bound prostaglandin E synthase-1; PGE, prostaglandin E; RANKL, receptor activator of NF-κB ligand; sRANKL, soluble RANK ligand; TLR4, toll-like receptor 4; TNF-α, tumor necrosis factor-α; TRAP, tartrate-resistant acid phosphatase.

1972
derived RANKL promotes the differentiation of precursor cells into mature osteoclasts [4,5]. Inflammatory bone-resorbing factors, such as LPS and IL-1, stimulate the mRNA expression of cyclooxygenase (COX)-2 and membrane-bound prostaglandin (PG) E synthase (mPGES)-1, leading to PGE₂ production by osteoblasts [6-8]. We previously reported that PGE₂ production is essential for inflammatory bone resorption, and PGE₂ is recognized by its receptor EP4 in osteoblasts, inducing the expression of RANKL and resulting in osteoclast differentiation [8,9].

Periodontitis is an inflammatory bone disease caused by the infection of mixed Gram-negative bacteria. The progression of periodontitis results in alveolar bone destruction and tooth loss. LPS is an outer membrane component of Gram-negative bacteria and contributes to the pathogenesis of periodontitis via toll-like receptor (TLR) 4 signaling. We established a novel mouse model for periodontitis and reported that the LPS-induced alveolar bone loss was attenuated in mPGES-1-deficient mice, suggesting that mPGES-1-mediated PGE₂ synthesis is essential for LPS-mediated bone loss in periodontitis [7].

(−)-Epigallocatechin-3-O-gallate (EGCG) is a green tea-derived catechin that exerts a variety of beneficial effects, including antioxidative and antibacterial activities [10,11]. A methylated derivative of EGCG, 3-O-methylated EGCG (EGCG3′Me), is also reported to exert biological activity, such as antiallergic effects [12]. Suzuki et al. [13] reported that the inhibitory activity of EGCG3′Me was higher than that of EGCG in a mouse type IV allergy model, probably due to the absorption efficiency from the intestine. However, Yano et al. [14] examined the suppressive effects of EGCG3′Me and EGCG in the expression of IgE receptor in human basophilic cells and conversely found that the effects of EGCG3′Me were lower than those of EGCG. Therefore, the biological roles of EGCG and EGCG3′Me are controversial in different disease models, and different rates of intestinal absorption may be involved in these compounds’ respective biological potencies.

We previously reported that EGCG suppresses LPS-induced bone resorption via the negative regulation of PGE₂ production by osteoblasts and that EGCG restored alveolar bone loss induced by LPS in a mouse model of periodontitis [15]. However, the effects of EGCG3′Me on bone resorption are not known. In this study, we examined the effects of EGCG3′Me on RANKL-dependent osteoclast differentiation and LPS-induced inflammatory bone resorption. We also elucidated the effects of EGCG3′Me on alveolar bone destruction in a mouse model of periodontitis.

Materials and methods

Animals and reagents

Newborn, 5-week-old, and 6-week-old mice of the ddY strain were obtained from Japan SLC, Inc. (Shizuoka, Japan). All procedures were performed in accordance with the institutional guidelines for animal research. Highly purified EGCG3′Me (purity ≥98%) was obtained from Tokiwa Phytochemical Co., Ltd. (Chiba, Japan). LPS from Escherichia coli was provided by Sigma-Aldrich Co. LLC. (St. Louis, MO, USA). Recombinant human soluble RANK ligand (sRANKL) was purchased from Peprotech Co., Ltd. (Rocky Hill, NJ, USA).

Culture of primary mouse osteoblastic cells

Primary osteoblastic cells (POBs) were isolated from newborn mouse calvariae after five routine sequential digestions with 0.1% collagenase (Roche Diagnostics GmbH, Mannheim, Germany) and 0.2% dispase (Roche Applied Science, Mannheim, Germany) as described previously [7]. POBs were collected from fractions 2–4 and combined, and cultured for 3 days in α-modified MEM (αMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C under 5% CO₂ in air. After POBs reached to confluence, they were trypsinized, counted, and used for the respective experiment.

Cocultures of mouse bone marrow cells and osteoblasts

Bone marrow cells (BMCs) were isolated from tibiae of 6-week-old mice as reported previously [4,6]. BMCs (2 × 10⁶ cells) and POBs (1 × 10⁶ cells) were cocultured with or without LPS (1 ng·mL⁻¹) and EGCG3′Me (3–30 μM) in αMEM containing 10% FBS for 7 days. The cells adhering to the well surface were stained for tartrate-resistant acid phosphatase (TRAP), and TRAP-positive multinucleated cells containing ≥3 nuclei per cell were counted as osteoclasts.

Bone-resorbing activity in organ cultures of mouse calvariae

Newborn mouse calvariae were collected and precultured for 24 h in BGJb medium with 0.1% bovine serum albumin (BSA) at 37 °C under 5% CO₂ in the air. Calvariae were treated with LPS (1 μg·mL⁻¹) in the presence or absence of EGCG3′Me and cultured for 5 days. The bone-resorbing activity was elucidated by measuring the increased medium calcium, as reported previously [8].
Measurement of the PGE2 content

Primary osteoblastic cells were cultured in αMEM containing 10% FBS, and the concentration of PGE2 in the conditioned medium was measured using an enzyme immunoassay system (EIA) (GE Healthcare UK, Ltd., Little Chalfont, UK). The cross-reactivity of the antibody in the EIA was calculated as follows: PGE2, 100%; PGE1, 7.0%; 6-keto-PGF1α, 5.4%; PGF2α, 4.3%; and PGD2, 1.0%.

Real-time PCR analysis

Primary osteoblastic cells were cultured for 24 h in αMEM with 1% FBS with or without LPS (1 ng·mL⁻¹) and EGCG3°Me (30 μM). Total RNA was isolated using ISOGEN (Nippon Gene Co., Ltd., Toyama, Japan), and cDNA was prepared from RNA via reverse transcription. For a real-time PCR analysis, 5 μg of RNA was mixed with SsoAdvanced SYBR green supermix (Bio-Rad, Hercules, CA, USA) and a PCR primer pair, and a quantitative PCR (qPCR) analysis was performed using ΔΔCq (Cq; quantification cycle) methods [16]. The expression level of the target gene was normalized to that of the reference gene, β-actin, and the ratio of the expression of the test group was compared with that of the control group.

The primer sequences for qPCR, as used in the previous studies [6,7,15], are shown in Table 1. The results are shown as the relative fold expression compared with the control.

IkB kinase assay

The IkB kinase (IKK) activity of IKKβ was elucidated in vitro using test tubes with or without EGCG3°Me (1 mM) using the Cyclex IKKα and β Assay/Inhibitor Screening Kit (CycLex Co., Ltd., Nagano, Japan) with the IKKβ, IkBα, and anti-phospho-IkBα antibodies.

Dual-luciferase reporter assay

Plasmid pNFκB-TA-Luc (0.4 μg) contained four tandem copies of the NF-κB consensus sequence with the firefly luciferase reporter gene (Clontech Laboratories, Inc., Mountain View, CA, USA) and the pGL4.74[hLuc/TK] plasmid (40 ng) contained the renilla luciferase reporter gene (Promega Corp., Fitchburg, WI, USA) as an internal control reporter vector. Both plasmids were transfected into POBs in cultures using Lipofectamine 2000 (Thermo Fisher Scientific Inc., Waltham, MA, USA) and cultured for 24 h with or without LPS (1 ng·mL⁻¹) and EGCG3°Me (30 μM). The luciferase activity was measured using the Dual-luciferase Reporter Assay System (Promega Corp.) with an ARVO MX multilabel/luminescence counter (Perkin Elmer Corp., Waltham, MA, USA).

Osteoclast differentiation from macrophages

Bone marrow macrophages (BMMs) were prepared by three days’ culture with M-CSF (100 ng·mL⁻¹), and cultured for 5 days with or without sRANKL (100 ng·mL⁻¹). RAW264.7 cells (a murine macrophage cell line) were also cultured for 5 days with or without sRANKL (100 ng·mL⁻¹). The TRAP-positive multinucleated cells that contained ≥3 nuclei per cell were counted as osteoclasts.

Organ cultures of mouse alveolar bone

Mandibular alveolar bones were collected from 5-week-old mice under a microscope and cultured for 24 h in BGJb medium with 0.1% BSA at 37 °C under 5% CO2 in the air. After 24 h, alveolar bones were treated with LPS (5 μg·mL⁻¹) in the presence or absence of EGCG3°Me and cultured for 5 days. The bone-resorbing activity was determined by measuring the concentration of calcium in the conditioned medium.

Measurement of alveolar bone mineral density in mice

Lipopolysaccharide (25 μg per mouse) with or without EGCG3°Me (100 μg per mouse) was injected into the lower gingiva of mice on days 0, 2, and 4 to establish an experimental model of periodontitis. The mandibular alveolar bones were collected on day 7, and the bone mineral density (BMD) of the alveolar bone was measured by dual X-ray absorptiometry (model DCS-600R; Aloka, Tokyo, Japan), as reported previously [7].
Statistical analyses

Data were analyzed using one-way ANOVA, followed by Tukey’s test for post hoc analysis. All data are presented as the means ± SEM, and all statistical analyses were performed using IBM SPSS Statistics Ver.23 software (Armonk, NY, USA).

Results

Effects of EGCG3'“Me on LPS-induced osteoclast formation and bone resorption

The structure of EGCG3'“Me is shown in Fig. 1A. To examine the effects of EGCG3'“Me on osteoclast differentiation, POBs and BMCs were cocultured in the presence or absence of LPS (1 ng·mL⁻¹) and various doses of EGCG3'“Me. LPS induced the formation of TRAP-positive osteoclasts in the coculture, but adding EGCG3'“Me (3–30 μM) dose dependently suppressed the LPS-induced osteoclast formation (Fig. 1B). In organ culture of mouse calvariae, EGCG3'“Me (3–30 μM) clearly inhibited the bone-resorbing activity induced by LPS (Fig. 1C).

PGE2 production and the mRNA expression of COX-2, mPGES-1, and RANKL in osteoblasts

We previously reported that PGE2 production by osteoblasts is essential for inflammatory bone resorption induced by LPS [7]. As EGCG3'“Me suppressed LPS-induced bone resorption, as shown in Fig. 1, we next examined the effects of EGCG3'“Me on PGE2 production and the expression of the related enzymes in mouse osteoblasts using real-time PCR. LPS (1 ng·mL⁻¹) induced PGE2 production and the mRNA expression of COX-2 and mPGES-1, key enzymes for PGE2 synthesis, and adding EGCG3'“Me (30 μM) clearly suppressed LPS-induced PGE2 production and expression of COX-2 and mPGES-1 (Fig. 2A,B). LPS is also known to induce the expression of RANKL mRNA in osteoblasts, and EGCG3'“Me clearly inhibited the LPS-induced expression of RANKL mRNA (Fig. 2B). To explore the molecular mechanism of EGCG3'“Me action, we performed an IKK activity assay in vitro and found that EGCG3'“Me directly suppressed the IKK enzyme activity (Fig. 2C). Using a reporter gene assay for NF-κB transcriptional activity, we found that EGCG3'“Me significantly attenuated the LPS-induced NF-κB transcriptional activity (Fig. 2D). These data suggest that EGCG3'“Me suppresses the LPS-induced COX-2/mPGES-1-mediated PGE2 production.
production via the negative regulation of NF-κB signaling in osteoblasts, resulting in the inhibition of osteoclast differentiation and bone resorption.

Effects of EGCG3’’Me on osteoclastogenesis from macrophages

To assess the direct action of EGCG3’’Me on osteoclast precursor cells, BMMs were generated from bone marrow cells by culturing with M-CSF (100 ng·mL⁻¹) and then further cultured for 5 days with sRANKL (100 ng·mL⁻¹) in the presence or absence of EGCG3’’Me. EGCG3’’Me (10 and 30 μM) dose dependently inhibited the RANKL-induced osteoclastogenesis (Fig. 3A). In the cultures of the osteoclast precursor cells RAW264.7, adding EGCG3’’Me (10 and 30 μM) suppressed RANKL-dependent osteoclast differentiation (Fig. 3B). The mRNA expression of osteoclast-specific genes, such as Nfatc1, cathepsin K (Ctsk), and Oscar, was greatly elevated in association with RANKL-induced osteoclast generation.

Fig. 2. The effects of EGCG3’’Me on PGE₂ production and the mRNA expression of related genes in osteoblasts. (A) The levels of PGE₂ in cultured medium of osteoblasts. POBs were cultured for 24 h with or without LPS (1 ng·mL⁻¹) and EGCG3’’Me (30 μM), and the conditioned medium was collected to measure the levels of PGE₂. (B) The mRNA expression of COX-2 (Cox2), mPGES-1 (mPges1), and RANKL (Rankl) in osteoblasts was analyzed using real-time PCR. POBs were cultured for 24 h with or without LPS (1 ng·mL⁻¹) and EGCG3’’Me (30 μM), and total RNA was isolated for real-time PCR. (C) IKK activity was determined in vitro with or without EGCG3’’Me (1 mM) by the IKK activity assay kit using IKKβ, IκBα, and anti-phospho-IκBα antibody. IKK activity was expressed as the % of the control without EGCG3’’Me. (D) NF-κB-mediated transcriptional activity was measured with or without EGCG3’’Me (30 μM). Plasmid pNFKB-TA-Luc (0.4 μg) and the pGL4.74[hLuc/TK] plasmid (40 ng) were transfected into mouse POBs, and the POBs were cultured for 24 h with or without LPS (1 ng·mL⁻¹) and EGCG3’’Me (30 μM). The luciferase activity was measured with the Dual-Luciferase Reporter Assay system. A significant difference between the two groups was indicated; **P < 0.01 and ***P < 0.001 vs. control, ##P < 0.01 and ###P < 0.001 vs. LPS.
in cultures of RAW264.7 cells. Adding EGCG3’Me significantly suppressed the expression of all of these genes in a real-time PCR analysis (Fig. 3C).

**Effects of EGCG3’Me on alveolar bone loss in a mouse model of periodontitis**

To determine whether or not EGCG3’Me exerted bone protective effects against periodontitis, we established alveolar bone organ cultures as an *in vitro* experimental model of periodontitis. Alveolar bones were collected from the mouse mandible and cultured for five days with or without LPS and EGCG3’Me. LPS-induced alveolar bone resorption was significantly suppressed by adding EGCG3’Me (Fig. 4A). We further examined the effects of EGCG3’Me on alveolar bone loss using an *in vivo* mouse model of periodontitis. The injection of LPS in the lower gingiva induced
the loss of BMD of alveolar bone, but co-injection of EGCG3’Me with LPS restored the LPS-induced alveolar bone loss (Fig. 4B). The image data of DXA clearly showed the loss of alveolar bone by LPS injection, and EGCG3’Me recovered the bone loss to the control level, as shown in the upper panels of Fig. 4B.

**Discussion**

(−)-Epigallocatechin-3-O-gallate has been reported to exert various biological functions, including antioxidant, anti-allergy, anticancer, and antibacterial activities [10,11,17]. EGCG3’Me is known to be contained in some green tea cultivates, such as the Japanese tea Benifuuki. The biological functions of EGCG3’Me are similar to those of EGCG, but the potency of these EGCGs in different disease models is controversial.

In this study, we showed that EGCG3’Me inhibited LPS-induced osteoclast differentiation and bone resorption in organ cultures of mouse calvariae (Fig. 1). In our previous study, the treatment of 30–90 μM EGCG dose dependently suppressed LPS-induced bone resorption [15], but 3–10 μM EGCG3’Me clearly suppressed the bone resorption in the present study. Therefore, the inhibitory potency of EGCG3’Me seems to be slightly stronger than that of EGCG in bone resorption. In a mouse model of periodontitis, LPS-induced bone resorption was suppressed by EGCG3’Me in organ culture of alveolar bone, and the alveolar bone loss was attenuated by the injection of EGCG3’Me into the lower gingiva in vivo. The potency of EGCG3’Me in this model is slightly stronger than that of EGCG [15]. The mode of retention of EGCG3’Me in the gingival tissues must be examined in order to compare the effects of EGCG3’Me and EGCG in this model.

A previous study reported that the 67-kDa laminin receptor (67LR) is a receptor for catechins, EGCG, and EGCG3’Me, but other catechins, such as catechin, epicatechin, and epigallocatechin, cannot bind to the 67LR [18,19]. The binding activity of EGCG to the 67LR was reported to be higher than that of EGCG3’Me, but the administration of EGCG3’Me resulted in stronger effects than that of EGCG in animal studies [20,21]. Further studies are needed to define the role of 67LR in the action of EGCG3’Me in target tissues.

In one clinical trial, the intake of Benifuuki tea showed stronger antihypertensive effects than Yabukita tea, which does not contain EGCG3’Me [20]. In a mouse type IV allergy model, the antiallergy activity of EGCG3’Me by oral administration was higher than that of EGCG [13]. Furthermore, Benifuuki tea extract exhibited a stronger antiobesity effect than did Yabukita tea extract in a mouse model of high-fat diet obesity [22]. These results suggest that the 3-O-methylation enhances EGCG’s biological functions in vivo.
However, the binding activity of EGCG3′Me to 67LR, a receptor for catechins, was lower than that of EGCG [19]. Oritani et al. [21] examined the plasma concentration profiles of EGCG3′Me and EGCG after oral administration and found that EGCG3′Me maintained a higher plasma concentration than EGCG, and the bioavailability of EGCG3′Me was 2.7-fold higher than that of EGCG in rats. Therefore, the potent activity of EGCG3′Me in vivo is probably based on its higher plasma concentration due to its efficient absorption from the intestine.

We previously reported that LPS recognizes TLR4, an LPS receptor in osteoblasts, and that LPS-TLR4 signaling induces PGE2-mediated bone resorption [7]. Kumazoe et al. [23] reported that EGCG suppressed the expression of TLR4 in adipose tissues and obesity-induced inflammation, suggesting that TLR4 may be a target molecule for EGCG and EGCG3′Me. In LPS-TLR4 signaling, NF-κB is a critical molecule for the subsequent transcription. NF-κB binds to an inhibitor of NF-κB (IκB)α and localizes to the cytosol without stimulation. On exposure to inflammatory stimuli, LPS-TLR4 signaling activates the IκKα/IKKβ/NEMO (IKKs) complex, and IKKs lead to the dissociation of IκBα/NF-κB complex. NF-κB then shifts to the nucleus to activate the transcription of various target genes. In the present study, EGCG3′Me suppressed the mRNA expression of COX-2, mPGES-1, and RANKL in osteoblasts, and the transcription of these genes is known to be regulated by NF-κB. Indeed, EGCG3′Me directly suppressed both the enzyme activity of IKK and the NF-κB-mediated transcriptional activity (Fig. 2C,D). Therefore, NF-κB may be a critical molecule to consider when discussing the mechanism underlying the activity of EGCG3′Me in bone tissues.

As a model of periodontitis, we used a mouse model and showed that LPS injection into the lower gingiva induces the loss of alveolar BMD. Ossola et al. [24,25] have shown the LPS-induced periodontitis in rats and reported the beneficial effects of treatment with methanandamide and cannabinoïd-2 receptor agonist, which may be useful for the oral health. Gurkan et al. [26] also used the rat experimental periodontitis induced by LPS and reported the therapeutic effects of vasoactive intestinal peptide by monitoring alveolar bone. It is known that the pathological mechanism of human periodontitis is complex; however, the LPS-induced experimental models using rats and mice are useful to monitor various beneficial compounds for periodontitis.

In cancer cells, previous studies have shown that EGCG binds to Fas and induces Fas-mediated apoptosis [27] and that it inhibits the phosphorylation of vimentin, an intermediate filament, to suppress cell proliferation [28]. Nomura et al. [29,30] examined the mechanism underlying the activity of EGCG in carcinogenesis and reported that EGCG suppresses Akt activity in the UVB-induced PI3K pathway and also inhibits TPA-induced NF-κB activation in mouse epidermal cells. Therefore, the target molecules for the action of EGCG and EGCG3′Me are different in each cell, but kinases such as IKK and Akt may be potential molecules for these EGCGs in target cells.

Using a mouse experimental model of periodontitis, we previously showed the potential effects of the green tea catechin EGCG in preventing alveolar bone loss [15]. Here, we showed that EGCG3′Me also prevents alveolar bone loss in mice. Cho et al. [31] reported the effects of orally administered EGCG on ligature-induced periodontitis in rats. As the bioavailability of EGCG3′Me is higher than that of EGCG, the oral administration of the green tea Benifuuki containing EGCG3′Me may be effective for preventing periodontitis, but further studies, such as clinical trials, are needed in order to define the role of EGCG3′Me in the pathogenesis of human periodontitis.

Acknowledgements

This work is supported in part by the Institute of Global Innovation Research in TUAT (MI and FG).

Author contributions

TT, CM, and MI conceived and designed the experiments. TT, RI, SY, and KW performed the experiments. TT, CM, MH, and FMWG analyzed the data. CM, MI, and MH contributed reagents/materials/analysis tools. TT wrote the manuscript. CM, MI, and FMWG reviewed and improved the manuscript.

References

1. Tanabe N, Maeno M, Suzuki N, Fujisaki K, Tanaka H, Ogiso B and Ito K (2005) IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. Life Sci 77, 615–626.
2. Lee YMM, Fujikado N, Manaka H, Yasuda H and Iwakura Y (2010) IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol 22, 805–816.
3. Suda K, Udagawa N, Sato N, Takami M, Itoh K, Woo JTT, Takahashi N and Nagai K (2004) Suppression of
Methylated EGCG prevents inflammatory bone loss

T. Tominari et al.

osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J Immunol 172, 2504–2510.

1 Yi, Z, Tian, X, Yang, Y, Pei, H, Zhao, M, Wang, Y, Zhang, Y, Wang, X, Gu, X, Wu, J, Guo, J, Zhang, Z, Chen, J, Wang, X, Zhang, L, and Zhang, Z (2010) Differential expression of osteoprotegerin in ankylosing spondylitis. J Rheumatol 37, 1973–1979.

2 Yasuda, H, Shima, N, Nakagawa, N, Yamaguchi, K, Kinosaki, M, Mochizuki, S, Tomoyasu, A, Yano, K, Goto, M, Murakami A et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95, 3597–3602.

3 Lacey, T, Tan, K, Dunstan, B, Elliott, C, Elliott, S, Hsu, S, Hawkins, D, Capparelli, E, Qian, K, Sarosi S et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165–176.

4 Hirata, M, Kobayashi, M, Takita, M, Matsumoto, C, Miyaura, C and Inada M (2009) Hyaluronan inhibits bone resorption by suppressing prostaglandin E synthesis in osteoblasts treated with interleukin-1. Biochem Biophys Res Commun 381, 139–143.

5 Fujimura, Y, Tachibana, H and Yamada K (2004) Lipid raft-associated catechin suppresses the FcεRI expression by inhibiting phosphorylation of the extracellular signal-regulated kinase1/2. FEBS Lett 556, 204–210.

6 Xu, X, Zhou XD and Wu CD (2010) Tea catechin EGCG suppresses the mgl gene associated with halitosis. J Dent Res 89, 1304–1308.

7 Maeda-Yamamoto M, Ema K, Monobe M, Tokuda Y and Tachibana H (2012) Epicatechin-3-O-(3′′-O-methyl)-gallate content in various tea cultivars (Camellia sinensis L.) and its in vitro inhibitory effect on histamine release. J Agric Food Chem 60, 2165–2170.

8 Suzuki M, Yoshino K, Maeda-Yamamoto M, Miyase T and Sano M (2000) Inhibitory effects of tea catechins and O-methylated derivatives of (-)-epigallocatechin-3-O-gallate on mouse type IV allergy. J Agric Food Chem 48, 5649–5653.

9 Yano, S, Fujimura Y, Umeda D, Miyase T, Yamada K and Tachibana H (2007) Relationship between the biological activities of methylated derivatives of (-)-epigallocatechin-3-O-gallate (EGCG) and their cell surface binding activities. J Agric Food Chem 55, 7144–7148.

10 Tominari T, Matsumoto C, Watanabe K, Hirata M, Grundler FM, Miyaura C and Inada M (2015) Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio 5, 522–527.

11 Wong ML and Medrano JF (2005) Real-time PCR for mRNA quantitation. Biotechniques 39, 75–85.

12 Adhami VM, Siddiqui IA, Ahmad N, Gupta S and Mukhtar H (2004) Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64, 8715–8722.

13 Tachibana H, Koga K, Fujimura Y and Yamada K (2004) A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 11, 380–381.

14 Fujiyama Y, Umeda D, Yano S, Maeda-Yamamoto M, Yamada K and Tachibana H (2007) The 67 kDa laminin receptor as a primary determinant of anti-allergic effects of O-methylated EGCG. Biochem Biophys Res Commun 364, 79–85.

15 Kurita I, Maeda-Yamamoto M, Tachibana H and Kamei M (2010) Antihypertensive effect of Benifuuki tea containing O-methylated EGCG. J Agric Food Chem 58, 1903–1908.

16 Inagaki, H, Sugitani Y, Setoguchi Y, Ito R, Maruki-Uchida H, Ichiyanagi T and Ito T (2013) Comparison of (-)-epigallocatechin-3-O-gallate (EGCG) and O-methyl EGCG bioavailability in rats. Biol Pharm Bull 36, 1577–1582.

17 Oritani Y, Setoguchi Y, Ito R, Maruki-Uchida H, Ichiyanagi T and Ito T (2013) Comparison of (-)-epigallocatechin-3-O-gallate (EGCG) and O-methyl EGCG bioavailability in rats. Biol Pharm Bull 36, 1577–1582.

18 Ichiyanagi T and Ito T (2013) Comparison of (-)-epigallocatechin-3-O-gallate (EGCG) and O-methyl EGCG bioavailability in rats. Biol Pharm Bull 36, 403–411.

19 Kumazoe M, Nakamura Y, Yamashita M, Suzuki T, Takamatsu K, Huang Y, Bae J, Yamashita S, Murata M, Yamada S et al. (2017) Green tea polyphenol epigallocatechin-3-gallate suppresses toll-like receptor 4 expression via up-regulation of E3 ubiquitin-protein ligase RNF216. J Biol Chem 292, 4077–4088.

20 Ossola CA, Surkin PN, Pugnaloni A, Mohn CE, Elverdin JC and Fernandez-Solari J (2012) Long-term treatment with methanandamide attenuates LPS-induced periodontitis in rats. Inflamm Res 61, 941–948.

21 Ossola CA, Surkin PN, Mohn CE, Elverdin JC and Fernandez-Solari J (2016) Anti-inflammatory and osteoprotective effects of cannabinoïd-2 receptor...
agonist HU-308 in a rat model of lipopolysaccharide-induced periodontitis. *J Periodontol* **87**, 725–734.

Gürkan A, Emingil G, Nizam N, Doğanavsargil B, Sezak M, Kütükçüler N and Atilla G (2009) Therapeutic efficacy of vasoactive intestinal peptide in *Escherichia coli* lipopolysaccharide-induced experimental periodontitis in rats. *J Periodontol* **80**, 1655–1664.

Hayakawa S, Saeki K, Suzuka M, Suzuki Y, Shoji Y, Ohta T, Kaji K, You A and Isemura M (2001) Apoptosis induction by epigallocatechin gallate involves its binding to Fas. *Biochem Biophys Res Commun* **285**, 1102–1106.

Ermakova S, Choi BY, Choi HS, Kang BS, Bode AM and Dong Z (2005) The intermediate filament protein vimentin is a new target for epigallocatechin gallate. *J Biol Chem* **280**, 16882–16890.

Nomura M, Kaji A, He Z, Ma WY, Miyamoto K, Yang CS and Dong Z (2001) Inhibitory mechanisms of tea polyphenols on the ultraviolet B-activated phosphatidylinositol 3-kinase-dependent pathway. *J Biol Chem* **276**, 46624–46631.

Nomura M, Ma W, Chen N, Bode A and Dong Z (2000) Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. *Carcinogenesis* **21**, 1885–1890.

Cho AR, Kim JH, Lee DE, Lee JS, Jung UW, Bak EJ, Yoo YJ, Chung WG and Choi SH (2013) The effect of orally administered epigallocatechin-3-gallate on ligature-induced periodontitis in rats. *J Periodontal Res* **48**, 781–789.